State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case
| dc.contributor.author | Petermann, Yuan | |
| dc.contributor.author | Said, Bibie | |
| dc.contributor.author | Cathignol, Annie | |
| dc.contributor.author | Sariko, Margaretha | |
| dc.contributor.author | Thoma, Yann | |
| dc.contributor.author | Mpagama, Stellah | |
| dc.contributor.author | Csajka, Chantal | |
| dc.contributor.author | Guidi, Monia | |
| dc.date.accessioned | 2025-11-13T09:03:02Z | |
| dc.date.issued | 2024-11-14 | |
| dc.description | SGD-2: Zero Hunger | |
| dc.description.abstract | The unique medical and socio-economic situation in each country affected by TB creates different epidemiological contexts, thus providing exploitable loopholes for the spread of the disease. Country-specific factors such as comorbidities, health insurance, social stigma or the rigidity of the health system complicate the management of TB and the overall outcome of each patient. First-line TB drugs are administered in a standardized manner, regardless of patient characteristics other than weight. This approach does not consider patient-specific conditions such as HIV infection, diabetes mellitus and malnutrition, which can affect the pharmacokinetics of TB drugs, their overall exposure and response to treatment. Therefore, the 'one-size-fits-all' approach is suboptimal for dealing with the underlying inter-subject variability in the pharmacokinetics of anti-TB drugs, further complicated by the recent increased dosing regimen of rifampicin strategies, calling for a patient-specific methodology. In this context, therapeutic drug monitoring (TDM), which allows personalized drug dosing based on blood drug concentrations, may be a legitimate solution to address treatment failure. This review focuses on rifampicin, a critical anti-TB drug, and examines its suitability for TDM and the socio-economic factors that may influence the implementation of TDM in clinical practice in resource-limited settings, illustrated by Tanzania, thereby contributing to the advancement of personalized TB treatment. | |
| dc.identifier.uri | https://doi.org/10.1093/jacamr/dlae182 | |
| dc.identifier.uri | https://dspace.nm-aist.ac.tz/handle/123456789/3428 | |
| dc.language.iso | en | |
| dc.publisher | Oxford University Press | |
| dc.title | State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case | |
| dc.type | Article |